PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩40 per share · Prices as of the 2026-10-02 close
Samik Pharmaceutical is pursuing a multi-year diversification strategy into CMO, long-acting injectables and logistics, while its last four quarters have alternated between profit and loss with rising volatility.
2025 consolidated revenue rose year over year to about KRW 60.0 billion, but net income attributable to owners swung to a loss.
The company posted profits in 2025Q3 and 2026Q1 but losses in 2025Q4 and 2026Q2, with earnings alternating over the last four quarters.
The 'Re-Leap 2030' mid-to-long-term strategy announced in early 2026 targets sales of KRW 130 billion and operating profit of KRW 11 billion by 2030.
The company registered a patent for its UniSphero long-acting injectable platform, though some industry commentary flagged the need for further technical validation.
The company listed on KOSDAQ via a SPAC merger in October 2025, raising capital that is funding capacity investments including an Incheon plant expansion and a planned second plant in Wonju.
Founded in 1973, Samik Pharmaceutical is a finished-dosage drug manufacturer focused on ethical (ETC) prescription medicines, primarily treatments for the three major chronic diseases: hypertension, diabetes, and hyperlipidemia.
As of end-2024 the company handled a total of 126 products, with cardiovascular agents accounting for 47% of sales and diabetes drugs for 10%. Key products include Sezar, Cadenza, Esol, Cregi, Piocita, Janumax, and Depaglu tablets.
Its contract manufacturing (CMO) business accounts for 12% of sales, serving 42 clients across 32 products, and the company has said it recently expanded its client base to 44.
It holds mass-production capability for metformin hydrochloride and bilayer tablet technology, and is also developing long-acting injectables (LAI) through its proprietary UniSphero platform. The company operates its own pharmaceutical logistics through wholly owned subsidiary Pharmbay.
It listed on KOSDAQ on October 27, 2025 via a merger with Hana Financial 28th SPAC.
Competitively, it faces small and mid-cap generic-focused rivals such as Samjin Pharmaceutical and Samil Pharmaceutical, and while smaller in scale than large pharma peers, it is attempting to differentiate through CMO and LAI new businesses.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | — | — | — |
| 2025Q3 | ₩15.8B | ₩1.1B | 6.8% |
| 2025Q4 | ₩15.2B | ₩49,344,090 | 0.3% |
| 2026Q1 | ₩15.5B | ₩900M | 6.0% |
| 2026Q2 | ₩15.7B | -₩200M | −1.4% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2024 | ₩55.9B | ₩3.7B | ₩3.5B | 6.6% | 6.8% | 23.8% |
| 2025 | ₩60B | ₩3.3B | -₩800M | 5.5% | −1.1% | 23.5% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-05
2025 consolidated revenue was approximately KRW 60.02 billion, up 7.5% from KRW 55.86 billion in 2024. Operating profit, however, fell to KRW 3.27 billion from KRW 3.68 billion, lowering the operating margin from 6.6% to 5.5%.
Net income attributable to owners swung from a profit of KRW 3.52 billion in 2024 to a loss of KRW 0.75 billion in 2025.
Quarterly figures show marked swings: 2025Q3 revenue was KRW 15.81 billion with operating profit of KRW 1.07 billion and net income of KRW 0.68 billion, a profitable quarter, while 2025Q4 revenue of KRW 15.24 billion produced near-breakeven operating profit of KRW 49 million but a net loss of KRW 3.34 billion. 2026Q1 returned to profit with revenue of KRW 15.51 billion, operating profit of KRW 0.93 billion, and net income of KRW 1.24 billion, but 2026Q2 revenue held at KRW 15.70 billion while operating profit turned negative at KRW -0.23 billion and net income posted a loss of KRW 77 million.
Over the trailing four quarters (2025Q3-2026Q2), cumulative net income attributable to owners was negative at roughly KRW -1.50 billion.
On the balance sheet, equity expanded from KRW 51.95 billion to KRW 68.98 billion and the debt ratio improved from 23.8% to 23.5%, indicating the capital base has remained solid despite the earnings volatility.
The global long-acting injectable (LAI) market is expected to enter a growth phase around 2026, driven by aging populations, rising chronic disease prevalence, and demand for improved medication adherence.
Korea's ETC pharmaceutical market has a stable demand base centered on chronic disease treatments for hypertension, diabetes, and hyperlipidemia, but it is also a mature market with intense competition among generic manufacturers.
Heungkuk Securities, in a report on Samjin Pharmaceutical, said this year's pharma-bio industry conditions overall would be difficult, and that demonstrating individual competitiveness matters more than absolute earnings scale at this juncture.
The CMO market is growing on rising outsourcing demand from small and mid-cap domestic pharma companies, and Samik Pharmaceutical is expanding its position there based on metformin hydrochloride mass-production and bilayer tablet technology.
Rivals such as Samjin Pharmaceutical and Samil Pharmaceutical compete with similar chronic-disease treatment portfolios.
Market commentary suggests the LAI segment's high technical barriers could make early movers scarce and valuable, though Pharm Edaily reported industry criticism that the drug loading in Samik's patented technology is too low and encapsulation efficiency varies significantly with loading changes, meaning technical stability has not been fully validated. Overall, the industry appears to be a mix of growth potential and unresolved validation risk.
In early 2026, the company unveiled its 'Re-Leap 2030' mid-to-long-term growth strategy, targeting consolidated sales of KRW 130 billion and operating profit of KRW 11 billion by 2030, more than double 2024 sales.
Key strategies include streamlining its contract sales organization (CSO), launching new hypertension combination drugs, expanding niche-market products, growing CMO orders, and diversifying into long-acting injectables.
Capacity expansion is proceeding in parallel: construction of an annex to the Incheon No. 1 plant, worth about KRW 7.27 billion, began in November 2025 and is targeted for completion, while a second plant for long-acting injectable production is planned to break ground in Wonju, Gangwon Province in 2027.
The wholly owned logistics subsidiary Pharmbay is targeting first-quarter 2027 for launching self-operated pharmaceutical distribution.
On the R&D front, the company is developing a first-generic version of a P-CAB class treatment for erosive gastroesophageal reflux disease and has submitted marketing authorization data to Korea's Ministry of Food and Drug Safety, awaiting approval.
It is also seeking to expand its pipeline using the UniSphero long-acting injectable platform and to pursue out-licensing opportunities with overseas pharmaceutical companies.
Samik Pharmaceutical posted a net loss for full-year 2025 and remains in a net loss position on a trailing four-quarter basis, making conventional price-to-earnings comparisons difficult.
Its price-to-book ratio sits near or below net asset value, suggesting the market is not pricing in a pronounced premium over book value. The company maintains a modest dividend policy, with a dividend yield that appears to run below the industry average.
Given that the profitable trend through 2024 has since shifted into a pattern of alternating losses and gains, whether the direction of earnings recovers is arguably a more relevant consideration than valuation multiples themselves.
Structural factors such as the initially limited free float following listing and the high ownership concentration of the founding family are also cited as influences on share price volatility.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-05
Under the 'Re-Leap 2030' strategy, the company has laid out a direction to cultivate CMO, long-acting injectables, and pharmaceutical logistics as new growth pillars. It has said it secured proprietary technology by registering a patent related to its UniSphero LAI platform.
The CMO business is on an expansion trend, having grown its client base to 44. This ongoing portfolio diversification is cited as a positive factor.
Samik Pharmaceutical raised capital through its October 2025 SPAC-merger listing on KOSDAQ. As a result, equity grew from KRW 51.9 billion in 2024 to KRW 69.0 billion in 2025, while the debt ratio remains low at 23.5%.
The fact that a substantial portion of facility investment is being funded from listing proceeds, limiting reliance on external borrowing, is cited as a positive.
2025 consolidated revenue rose 7.5% year over year to about KRW 60.0 billion, and the company posted operating and net profits in both 2025Q3 and 2026Q1. Revenue staying stable in the KRW 15 billion range per quarter points to a degree of downside resilience in the core business.
2025Q4 net loss was a substantial KRW -3.34 billion, and 2026Q2 operating profit also turned negative at KRW -0.23 billion.
While revenue stayed relatively steady in the KRW 15 billion range each quarter, the earnings line has swung significantly, reducing predictability of profitability, a factor cited as a bearish consideration.
Regarding the long-acting injectable platform, industry critics noted that drug loading is too low and encapsulation efficiency varies significantly with loading changes, meaning technical stability has not been fully validated.
Some analysis also suggests development has not yet reached the stage of a commercialization-ready formulation, implying it will take time before the pipeline meaningfully contributes to revenue.
At the time of listing, the founding family and related parties, 15 individuals in total, held a combined stake of 63.4%. With the free float structurally limited, there have been episodes of large price swings driven by thematic trading flows.
This ownership structure and liquidity profile are cited as factors that can amplify short-term share price volatility.
Recent quarterly results have alternated between profit and loss, with a particularly large net loss recorded in 2025Q4. If cost increases tied to expanded new-business investment continue, near-term earnings stability could be further affected. Investors should watch upcoming quarterly results to see whether the earnings trajectory stabilizes.
Some industry voices have argued that further validation is needed for the technical maturity of the long-acting injectable platform. Additional time and investment will be required before clinical application and commercialization, and delays could affect the pace of executing the Re-Leap 2030 growth strategy.
Ownership by the founding family and related parties is high, and the free float remains structurally limited. Given the sharp price swings seen driven by thematic trading around the SPAC-merger listing, volatility tied to trading volume and supply-demand dynamics could persist going forward.
2026Q3 earnings are expected to be released. This will be the first indicator of whether the earnings line recovers following the 2026Q2 operating loss.
This is the targeted completion timeframe for the Incheon No. 1 plant annex. Completion would confirm whether CMO and proprietary product manufacturing capacity has expanded as planned.
This is the target launch timeframe for subsidiary Pharmbay's self-operated pharmaceutical logistics. It is the point to check whether operations begin and whether logistics cost savings materialize.
Investors should confirm whether construction begins and the schedule is finalized for the second plant in Wonju, Gangwon Province, intended for long-acting injectable production.
It will be important to track whether the Ministry of Food and Drug Safety grants marketing authorization for the first-generic P-CAB class reflux disease treatment.
Samik Pharmaceutical is executing a mid-to-long-term strategy to expand from its ETC drug manufacturing base into CMO, long-acting injectables, and pharmaceutical logistics.
Full-year 2025 revenue grew year over year, but net income turned to a loss, and earnings volatility has increased with profits and losses alternating over the last four quarters.
Backed by capital raised through its listing, the company continues to invest in capacity, including the Incheon plant expansion and a planned second plant in Wonju, alongside R&D, and has outlined the 'Re-Leap 2030' strategy targeting more than double sales by 2030.
However, technical validation of the long-acting injectable platform, the supply-demand structure stemming from concentrated founding-family ownership, and the predictability of quarterly results remain variables to monitor.
Investors will want to track upcoming quarterly results, facility completion and start-up schedules, and drug approval progress to gauge the pace of strategy execution.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.